This 2020 electron microscope image provided by the National Institute of Allergy and Infectious Diseases - Rocky Mountain Laboratories shows SARS-CoV-2 virus particles which cause COVID-19, isolated from a patient in the U.S., emerging from the surface of cells cultured in a lab. According to a study released in The Lancet Global Health on Wednesday, Oct. 27, 2021, Fluvoxamine, a cheap antidepressant, reduced the need for hospitalization among high-risk adults with COVID-19. (NIAID-RML via AP)
By Carla K. Johnson
A cheap antidepressant reduced the need for hospitalization among high-risk adults with COVID-19 in a study hunting for existing drugs that could be repurposed to treat coronavirus.
Researchers tested the pill used for depression and obsessive-compulsive disorder because it was known to reduce inflammation and looked promising in smaller studies.
They've shared the results with the U.S. National Institutes of Health, which publishes treatment guidelines, and they hope for a World Health Organization recommendation.
“If WHO recommends this, you will see it widely taken up,” said study co-author Dr. Edward Mills of McMaster University in Hamilton, Ontario, adding that many poor nations have the drug readily available. “We hope it will lead to a lot of lives saved.”
The pill, called fluvoxamine, would cost $4 for a course of COVID-19 treatment. By comparison, antibody IV treatments cost about $2,000 and Merck's experimental antiviral pill for COVID-19 is about $700 per course. Some experts predict various treatments eventually will be used in combination to fight the coronavirus.
Researchers tested the antidepressant in nearly 1,500 Brazilians recently infected with coronavirus who were at risk of severe illness because of other health problems, such as diabetes. About half took the antidepressant at home for 10 days, the rest got dummy pills. They were tracked for four weeks to see who landed in the hospital or spent extended time in an emergency room when hospitals were full.
In the group that took the drug, 11% needed hospitalization or an extended ER stay, compared to 16% of those on dummy pills.
The results, published Wednesday in the journal Lancet Global Health, were so strong that independent experts monitoring the study recommended stopping it early because the results were clear.
Questions remain about the best dosing, whether lower risk patients might also benefit and whether the pill should be combined with other treatments.
The larger project looked at eight existing drugs to see if they could work against the pandemic virus. The project is still testing a hepatitis drug, but all the others — including metformin, hydroxychloroquine and ivermectin — haven't panned out.
The cheap generic and Merck's COVID-19 pill work in different ways and “may be complementary,” said Dr. Paul Sax of Brigham and Women’s Hospital and Harvard Medical School, who was not involved in the study. Earlier this month, Merck asked regulators in the U.S. and Europe to authorize its antiviral pill.
___
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.
The two-week COP26 climate conference has now ended with leaders reaching a deal, but so far the deal is getting mixed reviews from climate experts across the globe. Chloe Demrovsky, president and CEO of Disaster Recovery Institute International, explains that while the agreement is a step forward in some ways, the world still has much more to work on in order to keep warming to below 2 degrees Celsius.
Jill and Carlo cover the latest with the infrastructure bill, the growing state rebellion over boosters, Trump's dereliction of duty on the pandemic, Taylor Swift's reign of cultural domination and more.
Aurora Cannabis CEO Miguel Martin joins Cheddar News' Closing Bell to discuss the company's latest earnings results, how it will achieve positive EBITDA by 2023, and the state of the cannabis industry amid potential U.S. federal legalization.
Moderna is defending its COVID-19 vaccine after a study found an increase in reports of myocarditis, which is an inflammation of the heart, in males ages 12 to 29 — about 13.3 cases in every 100,000 subjects. The pharmaceutical giant said the benefits of the vaccine outweigh the risk of the possible negative side effect.
The parent company of North Face, Vans and Supreme, VF Corp, released its fourth annual "Made for Change" sustainability and responsibility report. It details the company's ongoing efforts to tackle social and climate related issues. This comes as climate experts continue to warn about the dangers of fast fashion and its impact on global CO2 emissions. Sean Cady, Vice President of Global Sustainability, Responsibility and Trade at VF Corporation, joins Cheddar News to discuss.
A jam-packed Freitag pod with Carlo and Baker: new Covid hotspots, Kyle Rittenhouse trial, Belarus making trouble for Europe, red-hot housing market, and how to manage a PR crisis the right way.
As the UN climate conference is set to wrap this week, we take a look at pledges that world leaders have signed onto so far and the most important developments to come out of COP26. Sandeep Pai, Senior Research Lead at the Just Transition Initiative, joins Cheddar Climate to discuss the most important global initiatives and biggest pledges made by global leaders, and whether or not they can truly make an impact if two of the world's biggest economies, China and Russia, did not attend and are not fully committed to major climate initiatives.
A group of health experts from around the world is issuing a dire warning about the climate crisis, saying that climate change is the greatest global health threat facing the world this century and is set to become the 'defining narrative of human health.' The Lancet medical journal stated that warning in its annual report, along with a policy brief for the United States detailing actions the country can take to stop millions of unnecessary deaths. Director of Climate for Health at EcoAmerica Rebecca Rehr joined Cheddar Climate to discuss.
The COP26 summit in Scotland is in its final days, and the U.N. has just released a draft of an agreement for more than 200 world leaders to sign on Friday. The draft urges nations to set more aggressive goals in cutting emissions, while also calling for coal to be phased out. Chloe Demrovsky, President and CEO of Disaster Recovery Institute International, joins Cheddar News to discuss this agreement.
SpaceX and NASA have collaborated on another successful launch sending four astronauts to the international space station. The international crew will stay in orbit aboard the ISS for six months.
